Readnour Robin Shane
Known title: DirectorCIK: 0001914883
Readnour Robin Shane's purchase track record
How the stock did after each of Readnour Robin Shane's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since March 29, 2022
Stock higher 6 months later
50%
3 months: 25%
Median 6-month return
-6.4%
3 months: -13.3%
Beat the S&P 500
50%
median -1.2% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/6/2024 | ANTX | $87K | -9.0% | -21.5% | -1.5% |
| 11/27/2024 | ANTX | $71K | -17.5% | -16.1% | -1.8% |
| 11/19/2024 | ANTX | $248K | +7.5% | +12.3% | +0.4% |
| 3/29/2022 | ANTX | $2.30M | -45.8% | +3.3% | -21.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ANTX | ▼ Sell | Open Market | 523 | $3K | 9/9/2026 | View on chart |
| ANTX | ▼ Sell | Open Market | 585 | $4K | 9/9/2026 | View on chart |
| ANTX | ▼ Sell | Open Market | 4,725 | $28K | 9/8/2026 | View on chart |
| ANTX | ▼ Sell | Open Market | 5,294 | $32K | 9/8/2026 | View on chart |
| ANTX | ▼ Sell | Open Market | 2,877 | $17K | 9/3/2026 | View on chart |
| ANTX | ▼ Sell | Open Market | 3,223 | $20K | 9/3/2026 | View on chart |
| ANTX | ▼ Sell | Open Market | 16,696 | $100K | 8/17/2026 | View on chart |
| ANTX | ▼ Sell | Open Market | 18,706 | $112K | 8/17/2026 | View on chart |
| ANTX | ▲ Buy | Grant | 9,077 | $0 | 12/19/2024 | View on chart |
| ANTX | ▲ Buy | Open Market | 5,000 | $7K | 12/10/2024 | View on chart |
| ANTX | ▲ Buy | Open Market | 5,000 | $7K | 12/10/2024 | View on chart |
| ANTX | ▲ Buy | Open Market | 12,289 | $18K | 12/9/2024 | View on chart |
| ANTX | ▲ Buy | Open Market | 18,483 | $26K | 12/9/2024 | View on chart |
| ANTX | ▲ Buy | Open Market | 12,711 | $18K | 12/6/2024 | View on chart |
| ANTX | ▲ Buy | Open Market | 6,517 | $9K | 12/6/2024 | View on chart |
| ANTX | ▲ Buy | Open Market | 25,000 | $35K | 11/27/2024 | View on chart |
| ANTX | ▲ Buy | Open Market | 25,000 | $35K | 11/27/2024 | View on chart |
| ANTX | ▲ Buy | Open Market | 12,500 | $17K | 11/26/2024 | View on chart |
| ANTX | ▲ Buy | Open Market | 12,500 | $17K | 11/26/2024 | View on chart |
| ANTX | ▲ Buy | Open Market | 25,000 | $29K | 11/20/2024 | View on chart |
| ANTX | ▲ Buy | Open Market | 25,000 | $29K | 11/20/2024 | View on chart |
| ANTX | ▲ Buy | Open Market | 75,000 | $78K | 11/19/2024 | View on chart |
| ANTX | ▲ Buy | Open Market | 75,000 | $78K | 11/19/2024 | View on chart |
| ANTX | ▼ Sell | Open Market | 706 | $15K | 1/12/2024 | View on chart |
| ANTX | ▼ Sell | Open Market | 719 | $16K | 1/12/2024 | View on chart |
| ANTX | ▼ Sell | Open Market | 1,869 | $41K | 1/10/2024 | View on chart |
| ANTX | ▼ Sell | Open Market | 1,800 | $39K | 1/10/2024 | View on chart |
| ANTX | ▼ Sell | Other | 285,156 | — | 3/29/2022 | View on chart |
| ANTX | ▼ Sell | Other | 333,135 | — | 3/29/2022 | View on chart |
| ANTX | ▼ Sell | Other | 61,491 | — | 3/29/2022 | View on chart |
| ANTX | ▲ Buy | Open Market | 70,716 | $1.1M | 3/29/2022 | View on chart |
| ANTX | ▲ Buy | Open Market | 82,618 | $1.2M | 3/29/2022 | View on chart |
| ANTX | ▼ Sell | Other | 71,839 | — | 3/29/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
AN2 Therapeutics: Failed Drug Potential Value Driver
Seeking Alpha reports that a previously failed drug from AN2 Therapeutics may become a significant value driver for the company. This development is relevant as it suggests potential new revenue or licensing opportunities. The stock is currently trading near its support level, with an average analyst target of $9.00.
AN2 Therapeutics: Failed Drug Potential Value Driver. Seeking Alpha reports that a previously failed drug from AN2 Therapeutics may become a significant value driver for the company. This development is relevant as it suggests potential new revenue or licensing opportunities. The stock is currently trading near its support level, with an average analyst target of $9.00.